A nail glue composition includes at least one cyanoacrylate of the formula CH.sub.2═C(CN)COOR, an anionic stabiliser, and an antioxidant stabiliser comprising at least one stabiliser compound selected from the group consisting of α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, δ-tocotrienol, and derivatives thereof. R is ethyl, methoxyethyl, ethoxyethyl, n-butyl or octyl or mixtures thereof. The at least one stabiliser compound is in an amount of at least 0.02 wt % of the nail glue composition.

The invention relates to a method of customizing a nail-biting and/or finger sucking treatment solution, and a kit for providing a nail-biting and finger sucking treatment that is customizable for a wide range of afflicted users seeking to break a persistent nail-biting and/or finger sucking habit. In exemplary embodiments, the composition kit includes two separate containers, a first container having a nail growth-promoting, waterproofing composition that may be applied directly on a user's nails; and a second container may include an additive for customizing a bitterness factor of the first composition. Typically, the first container includes an applicator such as a brush. To facilitate adding the additive in a manner that is easily customizable, the second container may include a dropper for adding small doses of the additive composition to the first composition. The customizable kit allows the user to safely adjust the bitterness so that the treatment remains effective.

Injectable prolonged-action compositions for use in the treatment of nail diseases, including potentially promoting the growth of the nail, or for use promoting the growth of the nail. The compositions are administered subcutaneously, and optionally as an implant. The compositions may be in solid or non-solid form and include one or more solid biodegradable sustained-release polymers, and optionally one or more active substances.

The beauty or skin-care treatment may be a single use system for providing a manicure or pedicure treatment or other beauty or skin-care service. Each primary packaging that may be provided with the beauty or skin-care treatment may contain a beauty or skin-care product that may be used in providing the treatments. The beauty or skin-care treatment may include multiple primary packages in the form of single-serve packaging provided collectively as a set. The set may be housed in the secondary packaging and packaged together to form a multi-step treatment. The beauty or skin-care products contained in the single-serve packaging may be made of ingredients beneficial to the skin and may include products to aid in sanitizing, exfoliating, nourishing, hydrating and moisturizing the skin.

The beauty or skin-care treatment may be a single use system for providing a manicure or pedicure treatment or other beauty or skin-care service. Each primary packaging that may be provided with the beauty or skin-care treatment may contain a beauty or skin-care product that may be used in providing the treatments. The beauty or skin-care treatment may include multiple primary packages in the form of single-serve packaging provided collectively as a set. The set may be housed in the secondary packaging and packaged together to form a multi-step treatment. The beauty or skin-care products contained in the single-serve packaging may be made of ingredients beneficial to the skin and may include products to aid in sanitizing, exfoliating, nourishing, hydrating and moisturizing the skin.

Keratin protein cosmetic compositions are provided that include at least one keratin protein derived from human hair and a base cosmetic solution. Methods of treatment are also provided.

The present invention relates generally to: the cosmetic or pharmaceutical use of avenanthramide L or an oat extract comprising avenanthramide L; avenanthramide L or an oat extract comprising avenanthramide L as a neurokinin-1 receptor NK1R antagonist; and a method for preparing of preparing avenalumic acid and/or avenanthramide L.

The present invention relates generally to: the cosmetic or pharmaceutical use of avenanthramide L or an oat extract comprising avenanthramide L; avenanthramide L or an oat extract comprising avenanthramide L as a neurokinin-1 receptor NK1R antagonist; and a method for preparing of preparing avenalumic acid and/or avenanthramide L.

Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting γc-cytokine activity involve raising neutralizing antibodies against each individual γc-cytokine family member/receptor subunit. However, success has been limited and often multiple γc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.

Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting γc-cytokine activity involve raising neutralizing antibodies against each individual γc-cytokine family member/receptor subunit. However, success has been limited and often multiple γc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.